Bosutinib may stop the disease progression for some ALS patients
A 12-week phase I dose-escalation trial open label has been launched in early 2021 in Japan to evaluate the safety and tolerability of Bosutinib.
Of the nine patients who drank 100-300 milligrams of bosutinib daily for 12 weeks, five stopped progressing, the remaining four remained progressing at the same pace.
Sorry, there were no replies found.
Log in to reply.